3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
2
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
491
Rectal Neoplasms
267
Colonic Neoplasms
218
Pancreatic Neoplasms
186
Stomach Neoplasms
181
Esophageal Neoplasms
134
Breast Neoplasms
118
Neoplasm Metastasis
116
Squamous Cell Carcinoma of Head and Neck
94
Head and Neck Neoplasms
92
Neoplasms
88
Adenocarcinoma Of Esophagus
67
Esophageal Squamous Cell Carcinoma
61
Carcinoma, Hepatocellular
54
Adenocarcinoma
40
Nasopharyngeal Carcinoma
33
Cholangiocarcinoma
32
Biliary Tract Neoplasms
26
Anus Neoplasms
26
Gastrointestinal Neoplasms
25
Carcinoma, Squamous Cell
25
Carcinoma, Non-Small-Cell Lung
25
Keratosis, Actinic
22
Gallbladder Neoplasms
21
Urinary Bladder Neoplasms
20
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Liver Neoplasms
20
Bile Duct Neoplasms
19
Ovarian Neoplasms
16
Carcinoma
16
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
29
Papillomavirus Vaccines
22
Vaccines
11
Human Papillomavirus Recombinant Vaccine nonavalent
11
Radiotherapy, Intensity-Modulated
7
Human Papillomavirus DNA Tests
7
Colposcopy
7
Cisplatin
7
Educational Status
6
Carboplatin
6
Blood Specimen Collection
6
Vaccines, Synthetic
5
Specimen Handling
5
Early Intervention, Educational
5
Vaginal Smears
4
Methods
4
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Surveys and Questionnaires
3
Patient Navigation
3
Paclitaxel
3
Imiquimod
3
Hepatitis A Vaccines
3
Cyclophosphamide
3
halofantrine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Papillomavirus Infections
×
Fluorouracil
×
Clear all
NCT02258659
2024-09-24
OPTIMA
University of Chicago
Phase 2
Completed
62 enrolled
13 charts
NCT02135419
2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3
Completed
4,446 enrolled
13 charts